Literature DB >> 22665054

Stathmin 1 is a potential novel oncogene in melanoma.

J Chen1, M Abi-Daoud, A Wang, X Yang, X Zhang, H E Feilotter, V A Tron.   

Abstract

In previous studies, we demonstrated that miR-193b expression is reduced in melanoma relative to benign nevi, and also that miR-193b represses cyclin D1 and Mcl-1 expression. We suggested that stathmin 1 (STMN1) might be a target of miR-193b. STMN1 normally regulates microtubule dynamics either by sequestering free tubulin heterodimers or by promoting microtubule catastrophe. Increased expression of STMN1 has been observed in a variety of human malignancies, but its association with melanoma is unknown. We now report that STMN1 is upregulated during the progression of melanoma relative to benign nevi, and that STMN1 is directly regulated by miR-193b. Using an experimental cell culture approach, overexpression of miR-193b using synthetic microRNAs repressed STMN1 expression, whereas inhibition of miR-193b with anti-miR oligos increased STMN1 expression in melanoma cells. The use of a luciferase reporter assay confirmed that miR-193b directly regulates STMN1 by targeting the 3'-untranslated region of STMN1 mRNA. We further demonstrated that STMN1 is overexpressed in malignant melanoma compared with nevi in two independent melanoma cohorts, and that its level is inversely correlated with miR-193b expression. However, STMN1 expression was not significantly associated with patient survival, Breslow depth, mitotic count or patient age. STMN1 knockdown by small-interfering RNA in melanoma cells drastically repressed cell proliferation and migration potential, whereas ectopic expression of STMN1 using lentivirus increased cell proliferation and migration rates. Subsequent gene expression analysis indicated that interconnected cytoskeletal networks are directly affected following STMN1 knockdown. In addition, we identified deregulated genes associated with proliferation and migration, and revealed that p21(Cip1/Waf1) and p27(Kip) could be downstream effectors of STMN1 signaling. Taken together, our study suggests that downregulation of miR-193b may contribute to increased STMN1 expression in melanoma, which consequently promotes migration and proliferation of tumor cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22665054     DOI: 10.1038/onc.2012.141

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  KIAA1199 promotes metastasis of colorectal cancer cells via microtubule destabilization regulated by a PP2A/stathmin pathway.

Authors:  Lei Zhao; Dejun Zhang; Qiong Shen; Min Jin; Zhenyu Lin; Hong Ma; Shaoyi Huang; Pengfei Zhou; Gang Wu; Tao Zhang
Journal:  Oncogene       Date:  2018-09-10       Impact factor: 9.867

2.  PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Authors:  Lucia B Jilaveanu; Fabio Parisi; Meaghan L Barr; Christopher R Zito; William Cruz-Munoz; Robert S Kerbel; David L Rimm; Marcus W Bosenberg; Ruth Halaban; Yuval Kluger; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

3.  miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α.

Authors:  Jianda Zhou; Dan Xu; Huiqing Xie; Jingtian Tang; Rui Liu; Jingjing Li; Shaohua Wang; Xiang Chen; Juan Su; Xiao Zhou; Kun Xia; Quanyong He; Jia Chen; Wei Xiong; Peiguo Cao; Ke Cao
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

4.  Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).

Authors:  Craig L Slingluff; Gina R Petroni; Kerrington R Molhoek; David L Brautigan; Kimberly A Chianese-Bullock; Amber L Shada; Mark E Smolkin; Walter C Olson; Alison Gaucher; Cheryl Murphy Chase; William W Grosh; Geoffrey R Weiss; Aubrey G Wagenseller; Anthony J Olszanski; Lainie Martin; Sofia M Shea; Gulsun Erdag; Prahlad Ram; Jeffrey E Gershenwald; Michael J Weber
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

5.  miR-193b directly targets STMN1 and inhibits the malignant phenotype in colorectal cancer.

Authors:  Feng Guo; Yang Luo; Yi-Fei Mu; Shao-Lan Qin; Yang Qi; Yi-Er Qiu; Ming Zhong
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

6.  Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer.

Authors:  Chien-Lun Chen; Ting Chung; Chih-Ching Wu; Kwai-Fong Ng; Jau-Song Yu; Cheng-Han Tsai; Yu-Sun Chang; Ying Liang; Ke-Hung Tsui; Yi-Ting Chen
Journal:  Mol Cell Proteomics       Date:  2015-06-16       Impact factor: 5.911

7.  Breast- and salivary gland-derived adenoid cystic carcinomas: potential post-transcriptional divergencies. A pilot study based on miRNA expression profiling of four cases and review of the potential relevance of the findings.

Authors:  Orsolya Kiss; Anna-Mária Tőkés; Sándor Spisák; Anna Szilágyi; Norbert Lippai; Borbála Székely; A Marcell Szász; Janina Kulka
Journal:  Pathol Oncol Res       Date:  2014-09-21       Impact factor: 3.201

8.  An underlying prognosis predictor of hepatocellular carcinoma: Oncoprotein 18.

Authors:  Shu Gong; Zhonghua Tao; Xiaoyan Liu; Lin Gan
Journal:  Biomed Rep       Date:  2013-11-06

9.  Merkel cell polyomavirus small T antigen mediates microtubule destabilization to promote cell motility and migration.

Authors:  Laura M Knight; Gabriele Stakaityte; Jennifer J Wood; Hussein Abdul-Sada; David A Griffiths; Gareth J Howell; Rachel Wheat; G Eric Blair; Neil M Steven; Andrew Macdonald; David J Blackbourn; Adrian Whitehouse
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

10.  The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer.

Authors:  T Hemdan; M Lindén; S B Lind; A V Namuduri; E Sjöstedt; T D de Ståhl; A Asplund; P-U Malmström; U Segersten
Journal:  Br J Cancer       Date:  2014-07-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.